I am also not a doctor, biloxi, so I asked the Des
Post# of 155333
(Total Views: 253)
Posted On: 07/22/2025 11:27:56 PM
Re: biloxiblues #155327
I am also not a doctor, biloxi, so I asked the Destroyer of Worlds (google AI) which was safer: Leronlimab or Ipilimumab?
AI says:
"Leronlimab appears to have a better safety profile than Ipilimumab based on available data, primarily from clinical trials.
Leronlimab Safety Profile:
Generally well-tolerated, with few grade 3 treatment-emergent adverse events reported in studies.
A phase 2 study in mild-to-moderate COVID-19 showed a significant reduction in serious adverse events (SAEs) in the leronlimab group compared to placebo.
Ipilimumab Safety Profile:
Associated with a higher risk of immune-related adverse events (irAEs) compared to other immune checkpoint inhibitors.
Common side effects include:
Diarrhea
Rash
Fatigue
Nausea and vomiting
Abdominal pain
Anorexia/weight loss
More severe irAEs can include:
Enterocolitis (inflammation of the intestines)
Hepatitis (inflammation of the liver)
Dermatitis (skin inflammation)
Neuropathy (nerve damage)
Endocrinopathy (hormone problems)
These irAEs can be severe or even fatal.
A systematic review indicated that ipilimumab, particularly in combination with nivolumab, showed the highest risk of developing Grade ≥3 treatment-related adverse events.
Important Considerations:
The information available regarding leronlimab's safety profile largely comes from studies related to COVID-19 and other indications, not specifically head-to-head comparisons with ipilimumab for the same disease contexts.
Ipilimumab's safety data is more extensive due to its longer history of clinical use in melanoma treatment.
It is crucial to remember that individual responses to treatment can vary.
Consulting with a healthcare professional is essential for personalized medical advice and assessment of risks and benefits for any treatment option.
In summary, while direct head-to-head comparisons are limited, the available data suggests that leronlimab may have a more favorable safety profile compared to ipilimumab, which is known for its potential for significant immune-related adverse events."
AI says:
"Leronlimab appears to have a better safety profile than Ipilimumab based on available data, primarily from clinical trials.
Leronlimab Safety Profile:
Generally well-tolerated, with few grade 3 treatment-emergent adverse events reported in studies.
A phase 2 study in mild-to-moderate COVID-19 showed a significant reduction in serious adverse events (SAEs) in the leronlimab group compared to placebo.
Ipilimumab Safety Profile:
Associated with a higher risk of immune-related adverse events (irAEs) compared to other immune checkpoint inhibitors.
Common side effects include:
Diarrhea
Rash
Fatigue
Nausea and vomiting
Abdominal pain
Anorexia/weight loss
More severe irAEs can include:
Enterocolitis (inflammation of the intestines)
Hepatitis (inflammation of the liver)
Dermatitis (skin inflammation)
Neuropathy (nerve damage)
Endocrinopathy (hormone problems)
These irAEs can be severe or even fatal.
A systematic review indicated that ipilimumab, particularly in combination with nivolumab, showed the highest risk of developing Grade ≥3 treatment-related adverse events.
Important Considerations:
The information available regarding leronlimab's safety profile largely comes from studies related to COVID-19 and other indications, not specifically head-to-head comparisons with ipilimumab for the same disease contexts.
Ipilimumab's safety data is more extensive due to its longer history of clinical use in melanoma treatment.
It is crucial to remember that individual responses to treatment can vary.
Consulting with a healthcare professional is essential for personalized medical advice and assessment of risks and benefits for any treatment option.
In summary, while direct head-to-head comparisons are limited, the available data suggests that leronlimab may have a more favorable safety profile compared to ipilimumab, which is known for its potential for significant immune-related adverse events."
(3)
(0)